QQQ   423.60 (-0.87%)
AAPL   181.45 (-0.06%)
MSFT   399.23 (-0.88%)
META   467.32 (-0.83%)
GOOGL   142.51 (+0.98%)
AMZN   167.99 (+0.54%)
TSLA   192.65 (-0.57%)
NVDA   669.55 (-3.60%)
NIO   6.03 (+1.17%)
AMD   163.38 (-1.39%)
BABA   75.76 (+3.58%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.62 (-0.11%)
CGC   3.39 (-4.24%)
GE   148.05 (-0.38%)
DIS   107.86 (-1.44%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.52 (-1.89%)
XOM   104.86 (+2.05%)
QQQ   423.60 (-0.87%)
AAPL   181.45 (-0.06%)
MSFT   399.23 (-0.88%)
META   467.32 (-0.83%)
GOOGL   142.51 (+0.98%)
AMZN   167.99 (+0.54%)
TSLA   192.65 (-0.57%)
NVDA   669.55 (-3.60%)
NIO   6.03 (+1.17%)
AMD   163.38 (-1.39%)
BABA   75.76 (+3.58%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.62 (-0.11%)
CGC   3.39 (-4.24%)
GE   148.05 (-0.38%)
DIS   107.86 (-1.44%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.52 (-1.89%)
XOM   104.86 (+2.05%)
QQQ   423.60 (-0.87%)
AAPL   181.45 (-0.06%)
MSFT   399.23 (-0.88%)
META   467.32 (-0.83%)
GOOGL   142.51 (+0.98%)
AMZN   167.99 (+0.54%)
TSLA   192.65 (-0.57%)
NVDA   669.55 (-3.60%)
NIO   6.03 (+1.17%)
AMD   163.38 (-1.39%)
BABA   75.76 (+3.58%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.62 (-0.11%)
CGC   3.39 (-4.24%)
GE   148.05 (-0.38%)
DIS   107.86 (-1.44%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.52 (-1.89%)
XOM   104.86 (+2.05%)
QQQ   423.60 (-0.87%)
AAPL   181.45 (-0.06%)
MSFT   399.23 (-0.88%)
META   467.32 (-0.83%)
GOOGL   142.51 (+0.98%)
AMZN   167.99 (+0.54%)
TSLA   192.65 (-0.57%)
NVDA   669.55 (-3.60%)
NIO   6.03 (+1.17%)
AMD   163.38 (-1.39%)
BABA   75.76 (+3.58%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.62 (-0.11%)
CGC   3.39 (-4.24%)
GE   148.05 (-0.38%)
DIS   107.86 (-1.44%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.52 (-1.89%)
XOM   104.86 (+2.05%)
NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

$16.35
-0.20 (-1.21%)
(As of 01:34 PM ET)
Today's Range
$16.03
$16.64
50-Day Range
$6.10
$16.55
52-Week Range
$2.70
$17.27
Volume
199,681 shs
Average Volume
457,966 shs
Market Capitalization
$713.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.17

Y-mAbs Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
13.0% Downside
$14.17 Price Target
Short Interest
Bearish
6.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Y-mAbs Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$1.41 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.66) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.44 out of 5 stars

Medical Sector

1741st out of 1,856 stocks

Pharmaceutical Preparations Industry

827th out of 870 stocks


YMAB stock logo

About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

YMAB Stock Price History

YMAB Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
YMAB Mar 2024 20.000 call
YMAB Mar 2024 10.000 call
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 3.3% Higher
Y mAbs Therapeutics (YMAB)
Y-mAbs Therapeutics Inc YMAB
Bison Slips on Ice at Yellowstone National Park
Y-mAbs Therapeutics: A Monoclonal Antibody Play
5 Most Promising Cancer Stocks According to Analysts
Q3 2023 Y-mAbs Therapeutics Inc Earnings Call
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2023
Today
2/21/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:YMAB
Fax
N/A
Employees
147
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.17
High Stock Price Target
$22.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-14.4%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-95,570,000.00
Pretax Margin
-20.36%

Debt

Sales & Book Value

Annual Sales
$65.27 million
Book Value
$2.50 per share

Miscellaneous

Free Float
34,243,000
Market Cap
$721.91 million
Optionable
Optionable
Beta
0.69
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report














YMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings
or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price target for 2024?

6 brokers have issued 12 month target prices for Y-mAbs Therapeutics' stock. Their YMAB share price targets range from $5.00 to $22.00. On average, they predict the company's stock price to reach $14.17 in the next twelve months. This suggests that the stock has a possible downside of 13.0%.
View analysts price targets for YMAB
or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2024?

Y-mAbs Therapeutics' stock was trading at $6.82 at the start of the year. Since then, YMAB stock has increased by 138.9% and is now trading at $16.29.
View the best growth stocks for 2024 here
.

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our YMAB earnings forecast
.

How can I listen to Y-mAbs Therapeutics' earnings call?

Y-mAbs Therapeutics will be holding an earnings conference call on Friday, March 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its quarterly earnings data on Monday, May, 8th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.16. The company earned $20.30 million during the quarter, compared to analyst estimates of $15.55 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 18.28% and a negative net margin of 20.75%. The business's revenue was up 93.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.64) earnings per share.

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics updated its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $80.0 million-$85.0 million, compared to the consensus revenue estimate of $82.4 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.14%), Nuveen Asset Management LLC (0.92%), Goldman Sachs Group Inc. (0.91%), Los Angeles Capital Management LLC (0.82%), Northern Trust Corp (0.75%) and Dimensional Fund Advisors LP (0.72%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, Johan Wedell-Wedellsborg, Thomas Gad and Vignesh Rajah.
View institutional ownership trends
.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMAB) was last updated on 2/21/2024 by MarketBeat.com Staff